- 베를린 독일|의료기기
BERLIN--(Korea Newswire) May 9, 2012 -- BIOTRONIK, a leading manufacturer of innovative medical technology, has developed the world‘s first implantable cardiac defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and cardiac resynchronization therapy pacemaker (CRT-P) with ProMRI(R) technology. ProMRI(R) allows patients requiring tachycardia and heart failure therapies to have access to magnetic resonance imaging (MRI) for the first time ever.* These new products -- the Lumax 740 ICD and CRT-D series and the Evia HF-T -- will be showcased at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions to be held May 9-11, 2012, in the United States in Boston, Massachusetts.
“The Lumax 740 and Evia HF-T series mark an entirely new era of innovation in implantable cardiac device technology,” commented Christoph Böhmer, Managing Director of BIOTRONIK. “The broad device and lead portfolios of both the Lumax 740 and Evia HF-T series offer physicians the unique opportunity to select the optimal device for each patient, as well as giving their patients access to MR scans.”
Böhmer continued, “BIOTRONIK's innovative ProMRI(R) technology represents a true milestone, and we are very proud to be presenting the new Lumax 740 and Evia HF-T devices, as well as our extensive selection of high quality and reliable leads at the Heart Rhythm 2012 Scientific Sessions. BIOTRONIK promises accuracy and unsurpassed safety in every product including proven reliability designed into our leads. Every single component, every process and every specification is deliberately and repeatedly tested and monitored. At BIOTRONIK, we do not just comply with industry quality standards, we take pride in exceeding them.”
In addition to being the world‘s first ICDs, CRT-Ds and CRT-Ps approved for MR scans, BIOTRONIK’s new Lumax 740 and Evia HF-T devices also offer unique therapy options such as BIOTRONIK Home Monitoring(R). Studies demonstrate that BIOTRONIK Home Monitoring(R) enables the early detection of atrial fibrillation and significantly reduces hospitalizations (COMPAS(1)) as well as unnecessary and inappropriate shocks (ECOST(2)).
BIOTRONIK's Education Programs at the HRS Congress
BIOTRONIK is committed to supporting exceptional, world-class education programs for physicians who are actively shaping the future of cardiovascular medicine. At Heart Rhythm 2012, BIOTRONIK is engaged in supporting the EPIC Alliance Meeting and the Max Schaldach Research Fellowship in Cardiac Pacing and Electrophysiology.
The Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology
The Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology is a $50,000 postdoctoral Heart Rhythm Society Research Fellowship in cardiac electrophysiology that will be awarded at the congress on Friday, May 11. The goal of the full-year postdoctoral award is to assist awardees in initiating world-class research. The award is presented in the name of Professor Max Schaldach, the inventor of the first German pacemaker and founder of BIOTRONIK, to support the research training of individuals in either basic or clinical electrophysiology.
The EPIC Alliance (Electrophysiologist International Community Alliance) supports female physicians and researchers working in the field of electrophysiology and is holding one of its international meetings at the Heart Rhythm Society congress.
Professor Jeanne E. Poole, a member of the EPIC Steering Committee from the University of Washington (USA), will chair the session which is designed to address topics aimed at informing and supporting women electrophysiologists.
“We invited women EPs and fellows-in-training to join our annual meeting during Heart Rhythm 2012 in Boston, MA.,” says Jeanne E. Poole, Professor of Medicine, University of Washington, Seattle, WA and EPIC Alliance Steering Committee member. “Women electrophysiologists who are interested in mentoring and collaborating for the purposes of career development and research opportunities are encouraged to become involved with the EPIC Alliance.”
To learn more about BIOTRONIK's education program as well as innovative technologies, visit us at booth no. 622.
About BIOTRONIK SE & Co. KG
As one of the world's leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success -- and deliver confidence and peace of mind to physicians and their patients worldwide.
For more information, visit: www.biotronik.com
*Approved and launched in the CE region. Not currently available in the United States.
(1) Mabo P. et. al., Eur Heart J 2012, 33 (9): 1105-1111.
(2) Kacet S, presentation at ESC Congress 2011 in Paris, France.
Senior Director, Global Communications
BIOTRONIK SE & Co. KG
+49 (0) 30 68905 1602